Meiosin as A Drug Target Or Biomarker (G388553)

Target Name: MEIOSIN

NCBI ID: G388553

MEIOSIN

Meiosin as A Drug Target Or Biomarker

MEIOSIN, also known as meiosin I, is a protein that plays a crucial role in the process of meiosis, which is the type of cell division that occurs in the germ cells (sperm and egg) during the development of an organism. Meiosin is responsible for the formation of the double chromatin structure in the germ cells, which is important for the genetic diversity that is passed on to the offspring.

Recent studies have identified MEIOSIN as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. In this article, we will explore the basic helix-loop-helix (BHLH) structure of MEIOSIN and its potential as a drug target, as well as its role as a biomarker for some diseases.

The BHLH structure of MEIOSIN is a protein that contains a nucleotide-binding oligomerization (NBO) domain, which is responsible for binding to DNA. The BHLH domain is composed of a specific amino acid sequence that is involved in the formation of a protein-DNA complex, allowing it to interact with the double chromatin structure that is formed during meiosis.

One of the unique features of the BHLH domain is its ability to form a stable complex with DNA in the presence of high concentrations of salt. This is important for the function of MEIOSIN, as it allows the protein to bind to the double chromatin structure and to facilitate the formation of this structure during meiosis.

In addition to its role in meiosis, the BHLH domain of MEIOSIN has also been shown to play a role in various cellular processes, including cell signaling, gene regulation, and DNA replication.

As a drug target, MEIOSIN has the potential to intervene in a variety of diseases. For example, MEIOSIN has been shown to be involved in the development and progression of various types of cancer, including breast, ovarian, and prostate cancer. Additionally, MEIOSIN has also been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

As a biomarker, MEIOSIN has been shown to be involved in a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, studies have shown that MEIOSIN levels are often elevated in cancer cells, and that inhibiting MEIOSIN function may be a promising strategy for cancer treatment. Additionally, MEIOSIN has also been shown to be involved in the development of neurodegenerative diseases, and may be a potential biomarker for these diseases.

In conclusion, MEIOSIN is a protein that plays a crucial role in the process of meiosis and has been shown to be involved in a variety of cellular processes. Its BHLH structure and its ability to form a stable complex with DNA in the presence of high concentrations of salt make it a potential drug target or biomarker for a variety of diseases. Further research is needed to fully understand the role of MEIOSIN in disease and to develop effective treatments.

Protein Name: Meiosis Initiator

Functions: Gatekeeper of meiotic initiation in both male and female germ cells. In complex with STRA8, directly activates the transcription of a subset of critical meiotic genes playing a central role in cell-cycle switching from mitosis to meiosis. Temporal expression of MEIOSIN is required for meiotic entry decision

The "MEIOSIN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MEIOSIN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets